Effects of the therapy combining calcium and vitamin D3 supplement with calcitonin on bone tissue density in patients with coronary heart disease complicated with chronic heart failure.
As a long-term multisystem disorder, chronic heart failure (CHF) can gravely affect on bone metabolism, prompting a severe bone loss and increasing predisposition to fractures and the development of osteoporosis. The aim of the study was to investigate whether in patients with CHF a therapy combining calcium and vitamin D3 supplement (Calcemin Advance) and calcitonin (Miacalcic) can help to prevent and treat osteopenia and osteoporosis. Using dual-energy X-ray absorptiometry, we measured bone mineral density (BMD) in 59 patients with coronary heart disease (CHD) complicated with chronic heart failure. Our results suggest that following the standard treatment protocol of CHD complicated with CHF resulted in significant BMD loss in the lumbar vertebrae, approaching the level of osteopenia. After taking a calcium and vitamin D3 supplement, patients with this heart disorder had significant increase of BMD in the lumbar vertebrae and in the femoral bone. Patients with CHD complicated with CHF and diagnosed osteoporosis taking Calcemin Advance did not experience osteoprotection outcome, rather their BMD continued to decrease. However, combined therapy with Miacalcic and Calcemin Advance was effective in significantly increasing L1, L2 - L4 BMD in these patients. We demonstrated effectiveness of using a calcium and vitamin D3 supplement, for patients with CHD complicated with CHF and diagnosed osteopenia. Patients with CHD complicated by CHF and diagnosed osteoporosis did not experience osteoprotective action when using Calcemin Advance. However, in these patients L1 lumbar vertebra BMD significantly increased after the combined therapy.